# Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

> **NCT02193958** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.** · enrollment: 55 (actual)

## Conditions studied

- AML
- CMML
- MDS

## Interventions

- **DRUG:** FF-10501-01

## Key facts

- **NCT ID:** NCT02193958
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2019-08-09
- **Final completion:** 2019-10-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193958, "Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02193958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*